AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the first patient was treated with 212Pb-ADVC001, a Targeted Alpha Therapy in development for the treatment of PSMA-positive metastatic Castration-Resistant Prostate Cancer (mCRPC).
AdvanCell reaches milestone as first prostate cancer patient dosed with 212Pb-ADVC001
- Post author:
- Post published:November 13, 2023
- Post category:uncategorized